[go: up one dir, main page]

RU2018103174A3 - - Google Patents

Download PDF

Info

Publication number
RU2018103174A3
RU2018103174A3 RU2018103174A RU2018103174A RU2018103174A3 RU 2018103174 A3 RU2018103174 A3 RU 2018103174A3 RU 2018103174 A RU2018103174 A RU 2018103174A RU 2018103174 A RU2018103174 A RU 2018103174A RU 2018103174 A3 RU2018103174 A3 RU 2018103174A3
Authority
RU
Russia
Application number
RU2018103174A
Other versions
RU2018103174A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018103174A publication Critical patent/RU2018103174A/ru
Publication of RU2018103174A3 publication Critical patent/RU2018103174A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2018103174A 2015-06-30 2016-06-30 Ингибиторы рекомбинантного белка человека enhancer of zeste homolog 2 RU2018103174A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562186550P 2015-06-30 2015-06-30
US62/186,550 2015-06-30
US201562241254P 2015-10-14 2015-10-14
US62/241,254 2015-10-14
US201662313207P 2016-03-25 2016-03-25
US62/313,207 2016-03-25
US201662332099P 2016-05-05 2016-05-05
US62/332,099 2016-05-05
PCT/IB2016/053929 WO2017002064A1 (en) 2015-06-30 2016-06-30 Enhancer of zeste homolog 2 inhibitors

Publications (2)

Publication Number Publication Date
RU2018103174A RU2018103174A (ru) 2019-08-01
RU2018103174A3 true RU2018103174A3 (ru) 2019-10-21

Family

ID=56360440

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018103174A RU2018103174A (ru) 2015-06-30 2016-06-30 Ингибиторы рекомбинантного белка человека enhancer of zeste homolog 2

Country Status (13)

Country Link
US (1) US20180162845A1 (ru)
EP (1) EP3317271B1 (ru)
JP (1) JP6816041B2 (ru)
KR (1) KR20180022834A (ru)
CN (1) CN107849032A (ru)
AU (1) AU2016286537B2 (ru)
BR (1) BR112017028616A2 (ru)
CA (1) CA2990474A1 (ru)
ES (1) ES2804749T3 (ru)
RU (1) RU2018103174A (ru)
TW (1) TW201708210A (ru)
UY (1) UY36758A (ru)
WO (1) WO2017002064A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
KR20190003699A (ko) * 2016-05-05 2019-01-09 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI837231B (zh) * 2018-11-29 2024-04-01 日商第一三共股份有限公司 含有ezh1/2雙重抑制劑之醫藥組合及其用途
EP4034535A4 (en) * 2019-09-26 2023-11-22 Novartis AG AZACHINOLINE COMPOUNDS AND USES THEREOF
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528270A (en) 2001-03-19 2005-10-28 Ono Pharmaceutical Co Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
NZ628762A (en) * 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
JP2016503009A (ja) * 2012-12-13 2016-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC Zesteホモログ2エンハンサー阻害剤
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EA030196B1 (ru) * 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Ингибиторы энхансера zeste гомолога 2
WO2014195919A1 (en) * 2013-06-06 2014-12-11 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9556157B2 (en) * 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9969716B2 (en) * 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MD4820C1 (ru) * 2014-06-17 2023-03-31 Pfizer Inc. Замещенные дигидроизохинолиноновые соединения
MA40848A (fr) * 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑

Also Published As

Publication number Publication date
TW201708210A (zh) 2017-03-01
AU2016286537A1 (en) 2018-01-18
UY36758A (es) 2016-12-30
RU2018103174A (ru) 2019-08-01
BR112017028616A2 (pt) 2018-09-04
ES2804749T3 (es) 2021-02-09
JP6816041B2 (ja) 2021-01-20
EP3317271B1 (en) 2020-05-13
WO2017002064A1 (en) 2017-01-05
US20180162845A1 (en) 2018-06-14
KR20180022834A (ko) 2018-03-06
AU2016286537B2 (en) 2019-01-17
JP2018522874A (ja) 2018-08-16
CN107849032A (zh) 2018-03-27
EP3317271A1 (en) 2018-05-09
CA2990474A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
BE2015C047I2 (ru)
BR0107597B1 (ru)
BR0009182B1 (ru)
BR0000126B1 (ru)
BR0000695B1 (ru)
BR0000763F1 (ru)
BR0001536B1 (ru)
BR0001684B1 (ru)
BR0001810B1 (ru)
BR0002033B1 (ru)
BR0002402B1 (ru)
BR0002435B1 (ru)
BR0002694B1 (ru)
BR0002802B1 (ru)
BR0002874B1 (ru)
BR0003166B1 (ru)
BR0003189B1 (ru)
BR0003208B1 (ru)
BR0003401B1 (ru)
BR0003686B1 (ru)
BR0003746B1 (ru)
BR0003751B1 (ru)
BR0003928B1 (ru)
BR0004687B1 (ru)
BR0005041B1 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200204